Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate

Eli Lilly's experimental obesity drug, eloralintide, showed significant weight loss results in a small early-stage (Phase 1) study, with patients losing up to 11.3% of their body weight over 12 weeks15.

The study enrolled 100 patients who received different doses or placebo for 12 weeks; weight loss ranged from 2.6% to 11.3%, depending on dose5.

Gastrointestinal side effects were reported to be relatively minimal, with 10% of patients experiencing diarrhea and 8% vomiting5.

Eloralintide belongs to the class of amylin mimetics, which slow digestion and increase feelings of fullness, differentiating them from other popular obesity drugs5.

The drug is considered a strong candidate within the amylin class and is moving to the next stage of clinical development, with more detailed data to be presented at an upcoming scientific conference5.

Sources:

1. https://medwatch.com/News/Pharma_Biotech/article18277914.ece

5. https://www.latimes.com/science/story/2025-06-16/lilly-experimental-obesity-drug-early-study